Canada Pension Plan Investment Board lowered its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 5.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,047,556 shares of the company's stock after selling 59,556 shares during the quarter. Eli Lilly and Company accounts for 0.8% of Canada Pension Plan Investment Board's investment portfolio, making the stock its 27th largest holding. Canada Pension Plan Investment Board owned 0.11% of Eli Lilly and Company worth $808,713,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also made changes to their positions in LLY. CWA Asset Management Group LLC lifted its holdings in shares of Eli Lilly and Company by 11.9% in the 4th quarter. CWA Asset Management Group LLC now owns 6,794 shares of the company's stock valued at $5,245,000 after buying an additional 724 shares during the period. Centerpoint Advisory Group acquired a new stake in Eli Lilly and Company in the fourth quarter valued at $514,000. M&T Bank Corp lifted its holdings in Eli Lilly and Company by 0.7% in the third quarter. M&T Bank Corp now owns 266,822 shares of the company's stock valued at $236,389,000 after acquiring an additional 1,867 shares during the period. Kentucky Trust Co purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth $834,000. Finally, Proficio Capital Partners LLC grew its stake in shares of Eli Lilly and Company by 30.2% during the 4th quarter. Proficio Capital Partners LLC now owns 6,739 shares of the company's stock worth $5,202,000 after purchasing an additional 1,562 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets
In related news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This trade represents a 14.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.14% of the stock is currently owned by insiders.
Eli Lilly and Company Trading Up 14.5 %
Eli Lilly and Company stock traded up $106.80 during trading on Friday, hitting $841.70. The company's stock had a trading volume of 10,843,294 shares, compared to its average volume of 3,427,703. The stock's fifty day moving average is $829.09 and its 200 day moving average is $820.35. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The stock has a market capitalization of $798.08 billion, a price-to-earnings ratio of 71.88, a P/E/G ratio of 1.40 and a beta of 0.51. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.
Wall Street Analyst Weigh In
A number of analysts recently commented on LLY shares. Berenberg Bank set a $970.00 price objective on shares of Eli Lilly and Company in a report on Thursday, January 16th. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and decreased their price target for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. Truist Financial raised their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. Morgan Stanley decreased their target price on Eli Lilly and Company from $1,146.00 to $1,124.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 9th. Finally, Citigroup dropped their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research report on Tuesday, January 28th. Two investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $1,012.00.
Check Out Our Latest Stock Report on Eli Lilly and Company
Eli Lilly and Company Profile
(
Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Further Reading
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
